Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain
tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor …

Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for
patients with glioblastoma, the most aggressive glioma, although individually variable, has …

Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …

PURPOSE: Biomarkers that predict response or toxicity to antiangiogenic therapy are sought
to favorably inform the risk/benefit ratio. This study evaluated the association of vascular …

Angiogenesis has emerged as a critical process for tumour progression. Identifying key
pathways involved in the regulation and promotion of angiogenesis has resulted in the …

Angiogenesis is essential for the growth of primary tumors and for their metastasis. This
process is induced by factors, such as vascular endothelial growth factors (VEGFs), that bind …

Objectives This study aimed to analyze the relationship between vascular endothelial
growth factor A (VEGFA) gene polymorphisms, plasma VEGFA, and the susceptibility of …

Hypertension and hypothyreoidism are frequent side effects of VEGFR-inhibitors. We
investigated whether hypertension or hypothyreoidism diagnosed during sunitinib treatment …

Tumor angiogenesis has been identified to play a critical role in tumor growth and tumor
progression, and is regulated by a balance of angiogenic and anti-angiogenic cytokines …

Background Gastrointestinal stromal tumors (GIST) mutational status is recognized factor
related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib …